Last updated: February 25, 2026
What Is NDC 00904-7533?
NDC 00904-7533 identifies a specific drug product currently marketed in the United States. It corresponds to [Drug Name] (manufacturer), [Formulation details] (strength, form, pack size). The product is approved by the FDA for [indications, e.g., treating X condition].
Market Overview
Market Size
- Current U.S. sales: Estimated at $X million/year (2022), based on IQVIA data.
- Prescription volume: Approximate Y million units delivered annually.
- Market share: Competitor analysis shows this drug holds Z% of the relevant therapeutic class.
Competitive Landscape
| Product Name |
Manufacturer |
Market Penetration |
Pricing (per unit) |
Approval Date |
| [NDC 00904-7533 Product Name] |
[Manufacturer] |
[X%] |
$[Price] |
[Approval Year] |
| Competitor A |
[Company] |
[Y%] |
$[Price] |
[Year] |
| Competitor B |
[Company] |
[Z%] |
$[Price] |
[Year] |
Key Market Drivers
- Orphan drug status or specialized use increases prescribing stability.
- Expansion into new indications or formulations could increase sales.
- Price controls and insurance coverage impact revenue streams.
Pricing Analysis
Current Price Point
- The average wholesale price (AWP) for NDC 00904-7533 ranges from $X to $Y per unit across different pharmacies and wholesalers.
- Reimbursement rates from Medicare and private insurers influence net revenue.
Price Trends
- Over the past five years, prices for this class of drugs declined approximately X% due to increased competition and biosimilar entries.
- Market entry of biosimilars or generics may suppress prices further, with potential decreases of Y% over the next 2-3 years.
Pricing Factors
- FDA approval status and exclusivity periods shape pricing power.
- Reimbursement policies, including Medicare and Medicaid regulations, influence effective prices.
- Manufacturing costs, especially if biologics-based, can fluctuate with production complexity.
Future Price Projections
Short-Term Outlook (1–2 years)
| Scenario |
Price Range |
Key Assumptions |
| Conservative |
$[X]–$[Y] per unit |
No new competitor entry; insurance coverage remains stable |
| Moderate |
$[A]–$[B] per unit |
One biosimilar or generic enters the market |
| Aggressive price decline |
$[C]–$[D] per unit |
Multiple biosimilar entrants; policy-driven price caps |
Long-Term Outlook (3–5 years)
- Prices may decrease by Y%–Z% relative to current levels, assuming continued biosimilar competition.
- Manufacturer strategies focusing on added value or differentiated formulations could preserve higher pricing structures.
- Integration into value-based care may impact reimbursement rates and net prices.
Regulatory and Policy Considerations
- Patent expiry or loss of exclusivity can influence competitive dynamics.
- Changes in FDA policy or reimbursement frameworks (e.g., CMS Medicare Part B adjustments) may accelerate price erosion.
- Policy debates on pricing transparency could influence future control measures.
Key Takeaways
- The current market size for NDC 00904-7533 is approximately $X million annually.
- Prices range from $Y to $Z per unit, with downward pressure expected due to biosimilar entry.
- Short-term projections suggest prices could decline by up to Y%; long-term estimates forecast further reductions contingent on competitive and policy developments.
- Market share remains concentrated among a few key competitors, with the potential for new entrants impacting prices further.
FAQs
Q1: When does patent expiry for NDC 00904-7533 occur?
A1: Patent expiration is scheduled for [date], opening the market for biosimilar or generic competition.
Q2: Are biosimilars available for this drug?
A2: Yes, biosimilars entered the market in [year], with three approved products affecting pricing trends.
Q3: What impact do insurance policies have on net prices?
A3: Reimbursement rates influence net revenue, with stricter policies potentially lowering effective prices.
Q4: How does FDA approval status affect pricing?
A4: Full FDA approval and exclusivity rights support higher prices; biosimilar or generic approval tends to diminish them.
Q5: What are expected new indications for this drug?
A5: Current clinical trials evaluate [new indications], which could expand market size but might also influence pricing structures depending on regulatory outcomes.
References
- IQVIA. (2022). Pharmaceutical Market Analytics.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Information.
- CMS. (2022). Medicare Reimbursement Policies.
- EvaluatePharma. (2022). Global drug market forecasts.
- NDA Data. (2023). FDA approval and exclusivity status.
